Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 278

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 7
Chunk 278
---
,435 12,341 7.0 %0.8 %11.1 %3.4 %Net revenues$56,334 $54,318 $58,054 3.7 %(6.4)%4.6 %(5.9)%

2024 Form 10-K   |  38

The following table details AbbVie's worldwide net revenues:Percent changeAt actual currency ratesAt constant currency ratesyears ended December 31 (dollars in millions)2024202320222024202320242023ImmunologyHumiraUnited States$7,142 $12,160 $18,619 (41.3)%(34.7)%(41.3)%(34.7)%International1,851 2,244 2,618 (17.5)%(14.3)%(13.2)%(11.8)%Total$8,993 $14,404 $21,237 (37.6)%(32.2)%(36.9)%(31.9)%SkyriziUnited States$10,086 $6,753 $4,484 49.3 %50.6 %49.3 %50.6 %International1,632 1,010 681 61.6 %48.3 %65.4 %50.3 %Total$11,718 $7,763 $5,165 50.9 %50.3 %51.4 %50.6 %RinvoqUnited States$4,259 $2,824 $1,794 50.8 %57.4 %50.8 %57.4 %International1,712 1,145 728 49.6 %57.3 %57.0 %60.7 %Total$5,971 $3,969 $2,522 50.4 %57.4 %52.5 %58.4 %OncologyImbruvicaUnited States$2,448 $2,665 $3,426 (8.1)%(22.2)%(8.1)%(22.2)%Collaboration revenues899 931 1,142 (3.5)%(18.5)%(3